Gabapentin
Gabapentin Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Partial-onset seizures (± secondary generalization) | Adults and pediatrics ≥3 years | Adjunctive only | FDA Approved |
| Postherpetic neuralgia (PHN) | Adults | Monotherapy | FDA Approved |
Gabapentin received initial FDA approval in 1993 for adjunctive epilepsy treatment and was subsequently approved for postherpetic neuralgia in 2002. It is one of the most widely prescribed medications in the United States, with over 45 million prescriptions annually, though the majority of use is off-label. It is important to note that gabapentin is approved only as adjunctive therapy for epilepsy — it is not approved as monotherapy for seizures. Additionally, gabapentin is not effective for generalized epilepsy syndromes.
Diabetic peripheral neuropathy: First-line recommendation by NICE, NeuPSIG, and the Canadian Pain Society. Evidence quality: High (multiple RCTs).
Fibromyalgia: Used as alternative to pregabalin, duloxetine, or milnacipran. Evidence quality: Moderate.
Generalized anxiety disorder: Limited controlled data. Evidence quality: Low.
Chronic low back pain (radicular): Some evidence for radiculopathy; no benefit for axial low back pain. Evidence quality: Low.
Restless legs syndrome: Off-label with gabapentin IR; gabapentin enacarbil (Horizant) is FDA-approved for this indication separately. Evidence quality: Moderate.
Alcohol withdrawal / alcohol use disorder: Emerging evidence, particularly for mild-moderate withdrawal. Evidence quality: Low–Moderate.
Gabapentin Dosing
Postherpetic Neuralgia — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| PHN — rapid titration | Day 1: 300 mg once; Day 2: 300 mg BID; Day 3: 300 mg TID | 600 mg TID (1800 mg/day) | 3600 mg/day | Efficacy demonstrated across 1800–3600 mg/day with comparable effects; no clear additional benefit above 1800 mg/day in trials (FDA PI) Due to saturable absorption, give TID (not BID) for better bioavailability |
Epilepsy — Adjunctive Therapy
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Partial-onset seizures — adults and ≥12 y | 300 mg TID | 300–600 mg TID (900–1800 mg/day) | 3600 mg/day | Maximum interval between doses should not exceed 12 hours Can be given with or without food; scored 600/800 mg tablets may be halved |
| Partial-onset seizures — pediatric (3–11 y) | 10–15 mg/kg/day in 3 divided doses | Ages 5–11: 25–35 mg/kg/day; Ages 3–4: 40 mg/kg/day; all in 3 divided doses | 50 mg/kg/day | Titrate over approximately 3 days to effective range; younger children require higher weight-based dosing Not established for children <3 years |
Renal Dosing Adjustments
| CrCl (mL/min) | Total Daily Dose | Dosing Schedule | Notes |
|---|---|---|---|
| ≥60 | 900–3600 mg/day | 300–1200 mg TID | Standard dosing |
| 30–59 | 400–1400 mg/day | 200–700 mg BID | Reduced frequency and dose |
| 15–29 | 200–700 mg/day | 200–700 mg once daily | Once-daily dosing |
| <15 | 100–300 mg/day | 100–300 mg once daily | Proportional dose reduction |
| Hemodialysis | Supplemental 125–350 mg | After each 4-hour dialysis session | Gabapentin is cleared by dialysis; supplemental dose required post-session |
Gabapentin absorption occurs via the L-amino acid transporter (LAT) in the proximal small bowel, which is capacity-limited. Bioavailability decreases as dose increases: approximately 60% at 900 mg/day but only 33–35% at 3600 mg/day. This means that doubling the dose does not double the plasma level. Splitting the daily dose into three equal portions (TID) maximizes the amount absorbed at each dose. Clinicians should be aware that at doses above 1800 mg/day, further dose increases yield diminishing returns in plasma exposure. Gabapentin enacarbil (Horizant) and the gastroretentive formulation (Gralise) were developed to overcome this absorption limitation but are separate products with their own indications and are not interchangeable with immediate-release gabapentin.
Gabapentin Pharmacology
Mechanism of Action
Despite its structural resemblance to GABA, gabapentin does not bind to GABA receptors or directly affect GABAergic transmission. Its primary therapeutic target is the α2δ-1 subunit of presynaptic voltage-gated calcium channels. By binding to this subunit with high affinity, gabapentin reduces calcium influx at nerve terminals and subsequently decreases the release of excitatory neurotransmitters, including glutamate, noradrenaline, and substance P. This dampening of excitatory signaling is thought to underlie both its anticonvulsant effect (reducing seizure propagation) and its analgesic action (modulating pain signal processing in the dorsal horn and higher pain centres). Gabapentin does not affect sodium channels or have activity at glutamate receptors, distinguishing it from most other anticonvulsants.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Saturable via L-amino acid transporter (LAT) in proximal small bowel; bioavailability ~60% at 900 mg/day, drops to ~33–35% at 3600 mg/day; Tmax 2–4 h; food has minimal effect on extent | Non-linear (dose-dependent) absorption is the defining PK feature; doubling the dose does not double exposure; TID dosing maximizes absorption; morphine co-administration increases gabapentin AUC by 44% |
| Distribution | Vd ~58 L (~0.8 L/kg); protein binding <3%; CSF concentrations ~20% of plasma; crosses blood-brain barrier via LAT1 | Negligible protein binding eliminates displacement interactions; no need to monitor free levels; CSF penetration adequate for CNS effects |
| Metabolism | Not metabolized in humans; no hepatic CYP enzyme involvement; no enzyme induction or inhibition | No hepatic drug-drug interactions; safe in hepatic impairment; no dosing adjustment needed for liver disease |
| Elimination | t½ 5–7 h; 100% renal elimination as unchanged drug; clearance directly proportional to CrCl; removed by hemodialysis | Short half-life necessitates TID dosing; dose reduction required in renal impairment (per CrCl); supplemental dose needed post-dialysis |
Gabapentin Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Somnolence / drowsiness | 19–21% | 19% in epilepsy trials (vs 9% placebo); 21% in PHN trials (vs 5% placebo); most common during initial titration; dose-related |
| Dizziness | 17–28% | 17% in epilepsy trials (vs 7% placebo); 28% in PHN trials (vs 8% placebo); counsel regarding driving and machinery |
| Ataxia / unsteadiness | 13% | 13% in epilepsy trials (vs 6% placebo); increases with age; more pronounced with concurrent CNS depressants |
| Fatigue | 11% | 11% in epilepsy trials (vs 5% placebo); usually improves with continued use |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nystagmus | 8% | 8% in epilepsy trials (vs 4% placebo); often subclinical but may indicate dose is approaching upper limit |
| Peripheral edema | 2–8% | More common in PHN trials (8% at ≥1800 mg/day vs 2% placebo); dose-dependent; increases with age |
| Nausea / vomiting | 3–4% | Generally mild; can take with food to minimize |
| Weight gain | 2–3% | Less pronounced than with pregabalin or valproate, but can occur over long-term use |
| Tremor | 7% | 7% in epilepsy trials (vs 3% placebo) |
| Diplopia / amblyopia | 6% | 6% in epilepsy trials (vs 2% placebo); visual effects are dose-related |
| Xerostomia (dry mouth) | 2–5% | More common in PHN populations |
| Constipation | 2–4% | Increase dietary fiber and fluids |
| Amnesia / abnormal thinking | 2% | Cognitive effects generally milder than with topiramate |
| Hostility / emotional lability (pediatric) | 5–6% | 5.2% hostility and 6% emotional lability in pediatric epilepsy trials (vs 1.3% placebo); monitor behavior in children |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Respiratory depression (especially with opioids/CNS depressants) | Rare (postmarketing; life-threatening) | Variable; especially early in therapy or dose escalation | FDA warning added to PI; monitor respiratory status when co-prescribed with opioids, benzodiazepines, or in patients with COPD/respiratory impairment. Consider lower starting dose. |
| DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) | Very rare | Typically 2–8 weeks | Discontinue immediately; evaluate organ involvement; do not rechallenge. |
| Anaphylaxis / angioedema | Very rare | After first dose or any time during treatment | Discontinue immediately; emergency treatment for airway/hemodynamic compromise. |
| Suicidal ideation (AED class effect) | 0.43% (AED class pooled data) | Within first weeks to months | Monitor mood and behavior; AED class-wide FDA warning; risk applies to all indications. |
| Withdrawal seizures (abrupt discontinuation) | Uncommon | Within days of abrupt cessation | Taper gradually over at least 1 week; may occur even in patients without epilepsy. |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Somnolence | 1.2% | Most common in adult epilepsy trials; usually occurs early in therapy |
| Ataxia / dizziness | 0.6–0.8% | Often improves with dose optimization; elderly are more susceptible |
| Behavioral effects (pediatric) | 1.3–1.6% | Hostility and emotional lability; unique pediatric concern |
The FDA has added a warning to the gabapentin label regarding serious, life-threatening, or fatal respiratory depression when co-administered with CNS depressants, especially opioids, or in patients with underlying respiratory impairment (e.g., COPD, obstructive sleep apnea, elderly). When gabapentin is co-prescribed with opioids, initiate at the lowest effective dose and monitor closely for sedation and respiratory depression. This risk also applies to pregabalin and other gabapentinoids.
Gabapentin Drug Interactions
Gabapentin has one of the most favorable drug interaction profiles of any anticonvulsant. It is not metabolized by hepatic CYP enzymes, is not protein-bound, and does not induce or inhibit any metabolic enzymes. This eliminates the metabolism-based and displacement interactions that complicate therapy with phenytoin, carbamazepine, and valproate. The clinically relevant interactions are limited to absorption effects and additive CNS depression.
Gabapentin Monitoring
- Renal FunctionBaseline, then periodically
RoutineGabapentin is 100% renally eliminated; clearance is directly proportional to CrCl. Dose reduction is required when CrCl falls below 60 mL/min. Especially important in elderly patients, who may have unrecognized renal impairment. - Sedation / Respiratory StatusOngoing, especially with opioid co-administration
RoutineMonitor for excessive somnolence, sedation, and respiratory depression when gabapentin is co-administered with opioids, benzodiazepines, or other CNS depressants, or in patients with underlying respiratory impairment (COPD, sleep apnea). - Behavioral / Mood ChangesEach visit, especially early in therapy
RoutineAED class-wide suicidality risk applies. In pediatric patients (3–12 y), monitor for hostility, emotional lability, hyperkinesia, and thought disorder, which occur at higher rates than placebo. - Pain / Seizure ControlEach visit
RoutineTherapeutic drug monitoring is not routinely required for gabapentin as clinical response guides dosing. However, if efficacy is questionable despite adequate dosing, checking a trough level (reference range 2–20 mcg/mL) may help assess whether saturable absorption is limiting drug exposure. - Signs of Misuse / DiversionOngoing in at-risk populations
Trigger-basedGabapentin has recognized abuse potential (particularly in opioid-use-disorder populations); now a Schedule V controlled substance in multiple US states. Monitor for dose escalation requests, concurrent substance use, and sourcing from multiple prescribers. - Peripheral EdemaPeriodically, especially in PHN patients
Trigger-basedDose-related and increases with age; assess at each visit in elderly patients and those on higher doses (≥1800 mg/day).
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to gabapentin or any excipient in the formulation (FDA PI)
Relative Contraindications (Specialist Input Recommended)
- Concurrent use with pregabalin — duplicative mechanism with no added efficacy and increased adverse effects
- Severe renal impairment (CrCl <15 mL/min) without dose adjustment — gabapentin accumulation can produce severe sedation and myoclonus
- Active substance use disorder (opioid use disorder in particular) — gabapentin has recognized misuse potential; several states classify it as Schedule V
Use with Caution
- Elderly patients — age-related renal decline increases exposure; higher risk of falls, ataxia, and peripheral edema
- Patients with respiratory impairment (COPD, sleep apnea) — increased respiratory depression risk, especially with concurrent opioids or sedatives
- Pregnancy — animal data show fetal harm; limited human data; use only if benefit justifies risk
- Abrupt withdrawal — taper over at least 1 week to avoid withdrawal symptoms (anxiety, insomnia, nausea, pain, sweating) and potential withdrawal seizures
There is evidence from case reports, human studies, and animal studies associating gabapentin with serious, life-threatening, or fatal respiratory depression when co-administered with CNS depressants, including opioids, or in patients with underlying respiratory impairment. When co-prescribing gabapentin with opioids or other CNS depressants, or in patients with respiratory compromise, monitor for symptoms of respiratory depression and sedation. Consider initiating gabapentin at a lower dose.
All AEDs, including gabapentin, carry an increased risk of suicidal thoughts and behavior. Patients should be monitored for emergence of depression, suicidal ideation, or unusual behavioral changes.
Patient Counselling
Purpose of Therapy
Gabapentin is a medication used to treat nerve pain (such as pain after shingles) or to help control seizures when used alongside other seizure medications. It works by calming overactive nerve signals. It should be taken regularly as prescribed — stopping suddenly can cause problems.
How to Take
Take gabapentin at evenly spaced intervals, usually three times a day, with or without food. If you are using the 600 or 800 mg tablets, you may break them in half at the score line, but use the other half within 28 days. If you take an antacid (such as Maalox or Mylanta), wait at least 2 hours before taking gabapentin. Swallow capsules whole. Measure the oral solution carefully with a proper measuring device.
Sources
- Viatris Specialty LLC. NEURONTIN (gabapentin) Capsules, Tablets, and Oral Solution — Full Prescribing Information. Revised April 2025. FDA LabelPrimary source for all FDA-approved indications, dosing schedules, contraindications, warnings, adverse reaction incidence data, and renal dosing table.
- Assertio Therapeutics. GRALISE (gabapentin) Extended-Release Tablets — Full Prescribing Information. FDA LabelReference for the gastroretentive gabapentin formulation approved for PHN; different PK profile from immediate-release.
- Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837-1842. doi:10.1001/jama.280.21.1837Landmark RCT in 229 PHN patients establishing gabapentin efficacy for neuropathic pain with significant pain reduction at 2 weeks.
- Rice AS, Maton S; Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double-blind, placebo controlled study. Pain. 2001;94(2):215-224. doi:10.1016/S0304-3959(01)00407-9Confirmatory PHN trial demonstrating gabapentin efficacy at 1800–3600 mg/day with pooled adverse event data.
- US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology. 1993;43(11):2292-2298. doi:10.1212/WNL.43.11.2292Pivotal adjunctive epilepsy trial that supported the original FDA approval for partial-onset seizures.
- Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0NeuPSIG systematic review recommending gabapentin and pregabalin as first-line for neuropathic pain; NNT of 6.3 for ≥50% pain reduction with gabapentin.
- National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in non-specialist settings. Clinical Guideline CG173. Updated 2020. NICE CG173NICE guideline recommending gabapentin or pregabalin as initial pharmacological options for neuropathic pain.
- Taylor CP, Angelotti T, Bhangoo SK. Pharmacology and mechanism of action of pregabalin: the calcium channel α2–δ subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137-150. doi:10.1016/j.eplepsyres.2006.09.008Definitive review of the α2δ subunit mechanism shared by gabapentin and pregabalin — binding reduces calcium influx and excitatory neurotransmitter release.
- Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-669. doi:10.2165/11536200-000000000-00000Head-to-head PK/PD comparison: gabapentin’s saturable absorption and dose-dependent bioavailability vs pregabalin’s linear pharmacokinetics.
- Gidal BE, DeCerce J, Bockbrader HN, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998;31(2):91-99. doi:10.1016/S0920-1211(98)00020-5Key PK study demonstrating saturable absorption: bioavailability ~39% at 3600 mg/day TID, with modest improvement using QID dosing at 4800 mg/day.
- Ahmed GF, Bathena SP, Brundage RC, et al. Pharmacokinetics and saturable absorption of gabapentin in nursing home elderly patients. AAPS J. 2017;19(2):551-556. doi:10.1208/s12248-016-0022-zPopulation PK in elderly nursing home patients: gabapentin clearance strongly correlated with GFR; saturable absorption parameters similar to younger adults.
- Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10(1):119-140. doi:10.1586/ern.09.136Comprehensive review confirming gabapentin’s absence of CYP-based drug interactions and favorable interaction profile in polypharmacy.
- Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403-426. doi:10.1007/s40265-017-0700-xReview documenting gabapentin misuse patterns and rationale for state-level scheduling as a controlled substance.